Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers

Imagem de Miniatura
Arquivos
art_SILVA_Efficacy_of_levofloxacin_amoxicillin_and_a_proton_pump_2015.PDF (177.63 KB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2015
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
Faculdade de Medicina / USP
Autores
QUEIROZ, Elaine Cristina Silveira de
LEE, Jin Hwa
Citação
CLINICS, v.70, n.5, p.318-321, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVES: The eradication of Helicobacter (H.) pylori allows peptic ulcers in patients infected with the bacteria to be cured. Treatment with the classic triple regimen (proton pump inhibitor, amoxicillin and clarithromycin) has shown decreased efficacy due to increased bacterial resistance to clarithromycin. In our country, the eradication rate by intention to treat with this regimen is 83%. In Brazil, a commercially available regimen for bacterial eradication that uses levofloxacin and amoxicillin with lansoprazole is available; however, its efficacy is not known. Considering that such a treatment may be an alternative to the classic regimen, we aimed to verify its efficacy in H. pylori eradication. METHODS: Patients with peptic ulcer disease infected with H. pylori who had not received prior treatment were treated with the following regimen: 30 mg lansoprazole bid, 1,000 mg amoxicillin bid and 500 mg levofloxacin, once a day for 7 days. RESULTS: A total of 66 patients were evaluated. The patients’ mean age was 52 years, and women comprised 55% of the sample. Duodenal ulcers were present in 50% of cases, and gastric ulcers were present in 30%. The eradication rate was 74% per protocol and 73% by intention to treat. Adverse effects were reported by 49 patients (74%) and were mild to moderate, with a prevalence of diarrhea complaints. CONCLUSIONS: Triple therapy comprising lansoprazole, amoxicillin and levofloxacin for 7 days for the eradication of H. pylori in Brazilian peptic ulcer patients showed a lower efficacy than that of the classic triple regimen.
Palavras-chave
Peptic ulcer therapy, Helicobacter pylori drug effects, levofloxacin, amoxicillin therapeutic use and adverse effects
URI
https://observatorio.fm.usp.br/handle/OPI/10769
Referências
  1. Bellelis Patrick, 2004, Sao Paulo Med. J., V122, P73, DOI 10.1590/S1516-31802004000200009
  2. Berning Marco, 2011, Therap Adv Gastroenterol, V4, P103, DOI 10.1177/1756283X10384171
  3. Coelho Luiz Gonzaga, 2013, Arq. Gastroenterol., V50, P81, DOI 10.1590/S0004-28032013005000001
  4. Coelho Luiz Gonzaga Vaz, 2004, Arq. Gastroenterol., V41, P71, DOI 10.1590/S0004-28032004000100014
  5. Coelho Luiz Gonzaga Vaz, 2005, Arq. Gastroenterol., V42, P128, DOI 10.1590/S0004-28032005000200012
  6. Coelho LGV, 1996, GED, V15, P53
  7. Silva Joyce Matie Kinoshita da, 2010, Rev. Inst. Med. trop. S. Paulo, V52, P125, DOI 10.1590/S0036-46652010000300002
  8. Di Caro S, 2012, WORLD J GASTROENTERO, V18, P5669, DOI 10.3748/wjg.v18.i40.5669
  9. Eisig Jaime Natan, 2011, Arq. Gastroenterol., V48, P261, DOI 10.1590/S0004-28032011000400008
  10. Eisig JN, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-38
  11. Malfertheiner P, 1997, GUT, V41, P8
  12. Felga G, 2010, J INFECT DEV COUNTR, V4, P712, DOI 10.3855/jidc.911
  13. Georgopoulos SD, 2013, EXPERT OPIN PHARMACO, V14, P211, DOI 10.1517/14656566.2013.763926
  14. Gisbert JP, 2013, SCAND J GASTROENTERO, V48, P652, DOI 10.3109/00365521.2013.786132
  15. Godoy APO, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-20
  16. Karczewska E, 2011, PHARMACOL REP, V63, P799
  17. LAMOULIATTE H, 1995, J CLIN GASTROENTEROL, V20, pS28, DOI 10.1097/00004836-199506001-00007
  18. Li YQ, 2010, WIEN KLIN WOCHENSCHR, V122, P413, DOI 10.1007/s00508-010-1404-3
  19. Megraud F, 2013, GUT MICROBES, V4, P1
  20. Mendonca S, 2000, HELICOBACTER, V5, P79, DOI 10.1046/j.1523-5378.2000.00011.x
  21. Navarro-Rodriguez T, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-56
  22. Nista EC, 2006, AM J GASTROENTEROL, V101, P1985, DOI 10.1111/j.1572-0241.2006.00716.x
  23. O'Connor A, 2013, HELICOBACTER, V18, P58, DOI 10.1111/hel.12075
  24. Owens RC, 2005, CLIN INFECT DIS, V41, pS144, DOI 10.1086/428055
  25. QUEIROZ DMM, 1993, AM J GASTROENTEROL, V88, P322
  26. Schrauwen RWM, 2009, NETH J MED, V67, P96
  27. Selgrad M, 2013, EUR J GASTROEN HEPAT, V25, P1257, DOI 10.1097/MEG.0b013e3283643491
  28. Seven G, 2011, TURK J GASTROENTEROL, V22, P582, DOI 10.4318/tjg.2011.0255
  29. Silva FM, 2010, HELICOBACTER, V15, P46, DOI 10.1111/j.1523-5378.2009.00734.x
  30. Yuan Yuhong, 2013, Cochrane Database Syst Rev, V12, pCD008337, DOI 10.1002/14651858.CD008337.pub2
  31. National Institutes of Health Consensus Development Conference Statement. 1994, February 7-9
  32. Pyloripac Retrat * Trademark: Lansoprazol 30 mg, Amoxicilina 500 mg, Levofloxacina 500 mg. Medley Indústria Famacêutica
  33. Micromedex - Drugs details

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC